Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17031687 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29623445 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL15614685 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL118138 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29352123 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL928189 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Acetic Acid SCHEMBL925230 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL925229 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29448201 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL15614718 | 0.94 | ADRB2 (0.88) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1076 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | claimed |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2025-11-06 | — | — | US | claimed |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | GLAXO GROUP LIMITED (GB) | 2025-08-26 | — | — | US | claimed |
| CN-116283512-B | Method for synthesizing vilanabro and salts thereof | 博诺康源(北京)药业科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | HOVIONE SCIENTIA LIMITED (IE) | 2025-02-13 | — | — | US | claimed |
| EP-4452924-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | Hovione Scientia Limited (IE) | 2024-10-30 | — | — | EP | claimed |
| EP-4403231-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2024-07-24 | — | — | EP | claimed |
| EP-3578169-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | GLAXO GROUP LTD (GB) | 2024-06-26 | — | — | EP | claimed |
| EP-3335707-B1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2024-04-17 | — | — | EP | claimed |
| US-20240041846-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2024-02-08 | — | — | US | claimed |
| WO-2008021142-A2 | PROCESS FOR MANUFACTURING LACTOSE | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | WO | claimed |
| WO-2008021858-A2 | PROCESS FOR MANUFACTURING LACTOSE | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | WO | claimed |
| WO-2006124556-A2 | INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE AND METHODS OF ADMINISTERING THE SAME | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | WO | claimed |
| US-20060239932-A1 | Pharmaceutical formulations comprising magnesium stearate | GLAXO GROUP LIMITED (GB) | 2006-10-26 | — | — | US | claimed |
| US-20060233716-A1 | Pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| US-20060210485-A1 | Pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | US | claimed |
| EP-1643974-A1 | INHALABLE PHARMACEUTICAL FORMULATIONS COMPRISING A SUGAR ESTER | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | claimed |
| WO-2006008173-A2 | PHARMACEUTICAL FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | claimed |
| WO-2005004846-A1 | PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239932-A1 | Pharmaceutical formulations comprising magnesium stearate | SLCO2A1, SLCO1B1, SLCO2B1 | ADRB2 3370/4885ADRB1 2804/4885SLC6A2 404/4885 |
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | AVPR2, CYP2D6, AVPR1B | ADRB2 145/4885ADRB1 144/4885SLC6A2 1129/4885 |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 8/4885SLC6A2 497/4885 |
| US-20060210485-A1 | Pharmaceutical formulations | SLCO2A1, SI, SLCO2B1 | ADRB2 2390/4885ADRB1 1809/4885SLC6A2 437/4885 |
| US-20250339413-A1 | COMBINATIONS OF MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 11/4885SLC6A2 474/4885 |
| US-20240041846-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 11/4885SLC6A2 560/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885SLC6A2 925/4885 |
| US-20060233716-A1 | Pharmaceutical formulations | SLCO2A1, SLCO1B3, SLCO1B1 | ADRB2 3286/4885ADRB1 2499/4885SLC6A2 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.